Stock Code: 4167

Savior Lifetec Corporation and Subsidiaries

Consolidated Financial Report and Independent Auditors' Review Report

Q1 of 2025 and 2024

Address: No. 1, Nanke 6th Rd., Sinshih Dist., Tainan City, Taiwan

Tel.: (06)505-1200

§ TABLE OF CONTENTS §

Independent Auditors' Report

To Savior Lifetec Corporation:

Foreword

We have reviewed the accompanying consolidated balance sheets of Savior Lifetec Corporation (the "Company") and its subsidiaries as of March 31, 2025 and 2024 and the consolidated statements of comprehensive income, the consolidated statements of changes in equity, and the consolidated statements of cash flows for the three-month periods ended March 31, 2025 and 2024, and the notes to the financial statements (including a summary of significant accounting). Compiling fairly presented consolidated financial statements according to the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and IAS 34 "Interim Financial Reporting" approved and issued into effect by the Financial Supervisory Commission is the responsibility of the management. The CPA is responsible for making conclusions based on the review result.

Scope

The CPA conducts review pursuant to ISRE 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." The procedures carried out during the review of consolidated financial statements include inquiries (mainly to the personnel in charge of financial and accounting matters), analytical procedures and other review procedures. The scope of a review is obviously narrower than the scope of an audit. Hence, the CPA may not identify the material matters that can be identified during an audit and, thus, cannot give audit opinions.

Conclusions

According to the auditing result, no facts that any and all of the material disclosures of the consolidated financial statements mentioned above were not prepared in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and the IAS 34 "Interim Financial Reporting" approved and issued into effect by the Financial Supervisory Commission and, thus, the consolidated financial position of Savior Lifetec Corporation and its subsidiaries as at March 31, 2025 and 2024, and the consolidated business performance and consolidated cash flow for the three-month periods ended March 31, 2025 and 2024 that were not fairly presented are identified.

Deloitte & Touche

Cheng Hsu-Jan, CPA	CPA, Hsieh Tung-Ju
Financial Supervisory Commission Approval No.: Jin-Guan-Zheng-Shen-Zi No. 1010028123	Financial Supervisory Commission Approval No.: Jin-Guan-Zheng-Shen-Zi No. 1090347472

May 2, 2025

Savior Lifetec Corporation and Subsidiaries

Consolidated Balance Sheet

March 31, 2025 and December 31 and March 31, 2024

Unit: NT$ thousand

		March 31, 2025		December 31, 2024		March 31, 2024	
Code	Assets	Amount	%	Amount	%	Amount	%
	Current assets						
1100	Cash and cash equivalents (Note 6)	$ 1,542,861	37	$ 1,358,063	31	$ 1,193,766	31
1110	Financial assets carried at fair value through profit or loss – current (Note 7)	72,185	2	39,097	1	114,578	3
1136	Financial assets carried at amortized cost – current (Notes 8, 11 and 27)	500,000	12	721,963	17	198,000	5
1150	Net notes receivable (Note 9)	2,152	-	2,040	-	2,898	-
1170	Net accounts receivable (Notes 9 and 18)	209,833	5	239,840	6	178,072	5
1200	Other accounts receivable (Note 9)	9,810	-	8,075	-	7,494	-
1220	Current Tax Assets	9,838	-	8,592	-	7,060	-
130X	Inventories (Note 10)	681,109	16	670,776	15	838,138	21
1410	Prepayments	52,449	1	55,859	1	65,136	2
1460	Non-Current Assets Held for Sale (Note 11)	-	-	136,501	3	-	-
1470	Other current assets	5,010	-	8,403	-	5,957	-
11XX	Total current assets	3,085,247	73	3,249,209	74	2,611,099	67
	Non-current assets						
1535	Financial assets carried at amortized cost – non-current (Notes 8 and 25)	74,292	2	54,040	1	4,040	-
1550	Investments Accounted for Using the Equity Method (Note 13)	147,176	3	146,782	3	146,466	4
1600	Property, plant and equipment (Notes 14 and 25)	742,114	17	728,057	17	829,362	21
1755	Right-of-use assets (Note 15)	167,385	4	166,840	4	264,175	7
1780	Intangible assets	1,459	-	1,455	-	2,027	-
1900	Other non-current assets (Note 25)	25,708	1	29,737	1	30,504	1
15XX	Total non-current assets	1,158,134	27	1,126,911	26	1,276,574	33
1XXX	Total assets	$ 4,243,381	100	$ 4,376,120	100	$ 3,887,673	100
Code	Liability and equity						
	Current liabilities						
2130	Contract liabilities – current (Note 18)	$ 3,071	-	$ 13,947	-	$ 6,055	-
2170	Accounts payable	40,356	1	42,239	1	56,928	2
2200	Other payables (Note 16)	117,915	3	123,405	3	110,307	3
2230	Current Tax Liabilities	99	-	99	-	8	-
2260	Liabilities directly related to non-current assets held for sale (Note 11)	-	-	500,000	12	-	-
2280	Lease liabilities – current (Note 15)	8,266	-	8,201	-	13,338	-
2399	Other current liabilities	2,055	-	2,548	-	60	-
21XX	Total current liabilities	171,762	4	690,439	16	186,696	5
	Non-current Liabilities						
2580	Lease liabilities – non-current (Note 15)	170,394	4	169,584	4	266,480	7
25XX	Total non-current liabilities	170,394	4	169,584	4	266,480	7
2XXX	Total liabilities	342,156	8	860,023	20	453,176	12
	Equity attributable to the company shareholders (Note 17)						
3110	Common stock	3,173,991	75	3,173,991	72	3,173,991	82
3200	Capital surplus	135,127	3	135,127	3	135,127	3
	Retained earnings						
3310	Legal reserve	7,637	-	7,637	-	4,634	-
3320	Special reserve	8,960	-	8,960	1	8,960	-
3350	Undistributed earnings	568,456	14	182,380	4	101,103	3
3300	Total retained earnings	585,053	14	198,977	5	114,697	3
31XX	Total equity attributable to owners of the company	3,894,171	92	3,508,095	80	3,423,815	88
36XX	Non-controlling interests	7,054	-	8,002	-	10,682	-
3XXX	Total equity	3,901,225	92	3,516,097	80	3,434,497	88
	Total liabilities and equity	$ 4,243,381	100	$ 4,376,120	100	$ 3,887,673	100

The attached notes are part of the Consolidated Financial Statements.

Chairman: Concord Consulting Inc.
Representative: Rebecca Lee

President: Chen Chih-Fang

Accounting Officer: Lin Kuo-Wei

Savior Lifetec Corporation and Subsidiaries

Consolidated Statement of Comprehensive Income

For the three-month periods ended March 31, 2025 and 2024

Unit: NT$ thousand, except earnings per share expressed in NT$

Code		January 1 to March 31, 2025 Amount	%	January 1 to March 31, 2024 Amount	%
4000	Operating revenue (Note 18)	$ 263,861	100	$ 259,192	100
5000	Operating costs (Notes 10 and 19)	(166,605)	(63)	(205,433)	(79)
5900	Operating Gross Profit	97,256	37	53,759	21
	Operating expenses (Notes 19 and 24)				
6100	Selling expenses	(16,391)	(6)	(9,080)	(4)
6200	Administrative expenses	(37,429)	(14)	(27,101)	(10)
6300	Research and development expenses	(16,672)	(7)	(20,740)	(8)
6000	Total operating expenses	(70,492)	(27)	(56,921)	(22)
6900	Net operating profit (loss)	26,764	10	(3,162)	(1)
	Non-operating income and expenses (Note 11 and 19)				
7100	Interest revenue	14,139	5	9,894	4
7010	Other income	2,305	1	2,044	1
7020	Other gains and losses	342,858	130	63,618	24
7050	Financial cost	(1,332)	-	(2,116)	(1)
7060	Share of profit or loss of affiliates recognized using the equity method	394	-	(495)	-
7000	Total non-operating income and expenses	358,364	136	72,945	28
7900	Net profit before tax	385,128	146	69,783	27
7950	Income tax expense (Note 20)	-	-	-	-
8200	Current net profit	385,128	146	69,783	27
8500	Current total comprehensive income	$ 385,128	146	$ 69,783	27

(Continued on the next page)

(Brought forward)

Code		January 1 to March 31, 2025 Amount	%	January 1 to March 31, 2024 Amount	%
	Profit attributable to:				
8610	Owners of the Company	$ 386,076	146	$ 71,073	27
8620	Non-controlling interests	(948)	-	(1,290)	-
8600		$ 385,128	146	$ 69,783	27
	Comprehensive Income Attributable To:				
8710	Owners of the Company	$ 386,076	146	$ 71,073	27
8720	Non-controlling interests	(948)	-	(1,290)	-
8700		$ 385,128	146	$ 69,783	27
	Earnings per share (Note 21)				
9750	Basic	$ 1.22		$ 0.22	
9850	Diluted	$ 1.21		$ 0.22	

The attached notes are part of the Consolidated Financial Statements.

Chairman: Concord Consulting Inc. President: Chen Chih-Fang Accounting Officer: Lin Kuo-Wei

Representative: Rebecca Lee

Savior Lifetec Corporation and Subsidiaries

Consolidated Statement of Changes in Equity

For the three-month periods ended March 31, 2025 and 2024

Unit: NT$ thousand

		Equity attributable to the company shareholders							
				Retained earnings					
Code		Common stock	Capital surplus	Legal reserve	Special reserve	Undistributed earnings	Total	Non-controlling interests	Total equity
A1	Balance on January 1, 2024	$ 3,173,991	$ 135,127	$ 4,634	$ 8,960	$ 30,030	$ 3,352,742	$ 11,972	$ 3,364,714
D1	Net income (loss) from January 1 to March 31, 2024	-	-	-	-	71,073	71,073	(1,290)	69,783
D3	Other comprehensive income after tax for the three-month period ended March 31, 2024	-	-	-	-	-	-	-	-
D5	Total comprehensive income for the three-month period ended March 31, 2024	-	-	-	-	71,073	71,073	(1,290)	69,783
Z1	Balance on March 31, 2024	$ 3,173,991	$ 135,127	$ 4,634	$ 8,960	$ 101,103	$ 3,423,815	$ 10,682	$ 3,434,497
A1	Balance on January 1, 2025	$ 3,173,991	$ 135,127	$ 7,637	$ 8,960	$ 182,380	$ 3,508,095	$ 8,002	$ 3,516,097
D1	Net income (loss) from January 1 to March 31, 2025	-	-	-	-	386,076	386,076	(948)	385,128
D3	Other comprehensive income after tax for the three-month period ended March 31, 2025	-	-	-	-	-	-	-	-
D5	Total comprehensive income for the three-month period ended March 31, 2025	-	-	-	-	386,076	386,076	(948)	385,128
Z1	Balance on March 31, 2025	$ 3,173,991	$ 135,127	$ 7,637	$ 8,960	$ 568,456	$ 3,894,171	$ 7,054	$ 3,901,225

The attached notes are part of the Consolidated Financial Statements.

Chairman: Concord Consulting Inc.
Representative: Rebecca Lee

President: Chen Chih-Fang

Accounting Officer: Lin Kuo-Wei

Savior Lifetec Corporation and Subsidiaries

Consolidated Statement of Cash Flows

For the three-month periods ended March 31, 2025 and 2024

Unit: NT$ thousand

Code		January 1 to March 31, 2025	January 1 to March 31, 2024
	Cash flows from operating activities		
A10000	Current net profit before tax	$ 385,128	$ 69,783
A20010	Income and Expenses:		
A20100	Depreciation expense	24,097	36,935
A20200	Amortization expense	472	627
A22400	Share of profit or loss of affiliates recognized using the equity method	(394)	495
A20900	Financial cost	1,332	2,116
A21200	Interest revenue	(14,139)	(9,894)
A23800	Loss (gain on recovery) on inventory devaluation and obsolescence	313	(5,087)
A22500	Loss on disposal of property, plant, and equipment	188	-
A29900	Gain on disposal of non-current assets held for sale	(339,689)	-
A20400	Net loss (gain) from financial assets carried at fair value through profit or loss	5,394	(28,999)
A24100	Unrealized net gain of foreign exchange	(1,625)	(914)
A30000	Changes of operating assets and liabilities		
A31115	Financial assets compulsorily measured at fair value through profit or loss	(38,482)	(37,364)
A31130	Notes receivable	(112)	(966)
A31150	Accounts receivable	31,592	97,019
A31180	Other accounts receivable	(153)	214
A31200	Inventories	(10,646)	26,993
A31230	Prepayments	3,410	(11,730)
A31240	Other current assets	3,393	417
A32125	Contract liabilities	(10,876)	(13,747)
A32150	Accounts payable	(2,004)	2,388
A32180	Other payables	(21,136)	1,178
A32230	Other current liabilities	(493)	(31)
A33000	Cash from operations	15,570	129,433
A33100	Interest received	12,565	11,425
A33300	Interest paid	(1,332)	(2,116)
A33500	Income Tax Paid	(1,246)	(2,134)
AAAA	Net cash inflow from operating activities	25,557	136,608

(Continued on the next page)

(Brought forward)

Code		January 1 to March 31, 2025	January 1 to March 31, 2024
	Cash flows from investing activities		
B00040	Acquisition of financial assets carried at amortized cost	($ 20,062)	($ 103,062)
B00050	Disposal of financial assets carried at amortized cost	221,963	111,120
B02700	Purchase of property, plant and equipment	(39,699)	(30,417)
B04500	Purchase of intangible assets	(476)	(55)
B02800	Disposal price of property, plant and equipment	546	-
B03800	Increase in guaranteed deposits paid	(97)	-
BBBB	Net cash inflow (outflow) from investing activities	162,175	(22,414)
	Cash flows from financing activities		
C04020	Lease liability principal repayment	(2,934)	(3,347)
CCCC	Net cash outflow from financing activities	(2,934)	(3,347)
EEEE	Current increase in cash and cash equivalents	184,798	110,847
E00100	Balance of cash and cash equivalents at beginning of period	1,358,063	1,082,919
E00200	Balance of cash and cash equivalents at ending of period	$ 1,542,861	$ 1,193,766

The attached notes are part of the Consolidated Financial Statements.

Chairman: Concord Consulting Inc. Representative: Rebecca Lee President: Chen Chih-Fang Accounting Officer: Lin Kuo-Wei

Savior Lifetec Corporation and Subsidiaries

Notes to the Consolidated Financial Statements

For the three-month periods ended March 31, 2025 and 2024

(Amounts in NT$ thousand, Unless Otherwise Specified)

1. Company History

Savior Lifetec Corporation (hereinafter referred to as the Company) was established on January 30, 2004, upon approval from the Ministry of Economic Affairs. The major business items of the Company and its subsidiaries (collectively, “the consolidated entities”) are the research, development, design, manufacture, and sale of carbapenem generics, injection generics, controlled-release generics, the development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms of the aforementioned products. The Company also provides medicine manufacturer technology and services. The Company has traded on Taipei Exchange as of September 8, 2015.

The consolidated financial statements are stated with the Company’s functional currency, i.e. NTD, as the presentation currency.

2. Date and Procedure for Approval of Financial Statements

The consolidated financial statements were approved by the Board of Directors on May 2, 2025.

3. Application of new and amended standards and interpretations

(1) Initial application of the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) (collectively, “IFRS accounting standards”) endorsed and issued into effect by the Financial Supervisory Commission (FSC).

Application of the amended IFRS accounting standards endorsed and issued into effect by the FSC as of 2025 does not have a significant effect on the consolidated entities’ accounting policies.

(2) IFRS standards endorsed by the FSC for application starting from 2026

New, amended and revised standards and interpretations	Effective date announced by IASB
Amendments to IFRS 9 and IFRS 7 "Classification and Measurement of Financial Instruments" regarding the application guidance for financial asset classification	January 1, 2026 (Note 1)

Note 1: These amendments are applicable to annual reporting periods beginning on or after January 1, 2026. Entities may also elect to apply them early, beginning January 1, 2025.

The application of the above IFRS standards endorsed by the FSC for application starting from 2026 is not expected to cause significant changes in the consolidated entities' accounting policies. As of the approval date of these consolidated financial statements, the Company continues to evaluate the impact of other amendments to standards and interpretations on its financial position and performance. The relevant impacts will be disclosed upon completion of the assessment.

(3) The IFRS accounting standards issued by the International Accounting Standards Board (IASB) but not yet endorsed and issued into effect by the FSC

New, amended and revised standards and interpretations	Effective date announced by the IASB (Note 1)
"Annual Improvements to IFRS Accounting Standards - Volume 11"	January 1, 2026
Amendments to IFRS 9 and IFRS 7 "Classification and Measurement of Financial Instruments" regarding the application guidance for derecognition of financial liabilities	January 1, 2026
Amendments to IFRS 9 and IFRS 7 "Contracts with Naturally Dependent Electricity"	January 1, 2026
Amendments to IFRS 10 and IAS 28 "Sale or Contribution of Assets Between an Investor and its Associate or Joint Venture"	To be decided
IFRS 17 "Insurance Contracts"	January 1, 2023
Amendments to IFRS 17	January 1, 2023
Amendments to IFRS 17 "Initial Application of IFRS 17 and IFRS 9 – Comparison Information"	January 1, 2023
IFRS 18 "Presentation and Disclosure in Financial Statements"	January 1, 2027
IFRS 19 "Subsidiaries without Public Accountability: Disclosures"	January 1, 2027

Note 1: Unless stated otherwise, the above New, Revised or Amended Standards and Interpretations are effective for annual reporting periods beginning on or after their respective effective dates.

IFRS 18 "Presentation and Disclosure in Financial Statements"

IFRS 18 will replace IAS 1 "Presentation of Financial Statements". The main changes in this standard include:

- The statement of profit or loss should classify income and expense items into operating, investing, financing, income tax, and discontinued operations categories.
- The income statement should present subtotals and totals for operating profit or loss, profit or loss before financing and taxes, and profit or loss.
- Provides guidance to strengthen aggregation and disaggregation requirements: The consolidated Company must identify assets, liabilities, equity, income, expenses, and cash flows arising from individual transactions or other events, and classify and aggregate them based on common characteristics, so that each line item presented in the primary financial statements has at least one similar characteristic. Items with dissimilar characteristics should be disaggregated in the primary financial statements and notes. The consolidated Company uses the label "other" for such items only when a more informative label cannot be found.
- Enhanced Disclosure of Management-Defined Performance Measures: When the consolidated Company conducts public communications outside of financial statements and communicates management's perspective on certain aspects of the consolidated Company's overall financial performance to users of financial statements, it should disclose information related to management-defined performance measures in a single note to the financial statements. This disclosure should include a description of the measure, how it is calculated, its reconciliation with subtotals or totals specified by IFRS accounting standards, and the impact of income tax and non-controlling interests on the reconciliation items.

Apart from the aforementioned impacts, as of the approval date of these consolidated financial statements, the Company continues to evaluate other potential impacts of the amendments to various standards and interpretations on its financial position and performance. The relevant impacts will be disclosed upon completion of the assessment.

4. Summary of significant accounting policies

(1) Statement of compliance

This consolidated financial report was prepared in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and IAS 34 "Interim Financial Reporting" approved and issued into effect by the Financial Supervisory Commission. The consolidated financial statements do not include all the IFRS disclosures required by the annual financial report.

(2) Basis of preparation

The consolidated financial statements have been prepared on the historical cost basis except for the financial instruments at fair value.

The fair value measurements are grouped into Levels 1 to 3 based on the degree to which the fair value measurement inputs are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

A. Level 1: The quoted price on an active market for identical assets or liabilities that are accessible to the Company on the measurement date (before adjustment).
B. Level 2: The inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
C. Level 3: The inputs that are not observable for assets or liabilities.

(3) Basis of consolidation

The consolidated financial statements incorporate the financial statements of the Company and the entities controlled by the Company (i.e. its subsidiaries). Operating income of subsidiaries acquired or disposed of during the period are included in the consolidated statements of comprehensive income from the effective date of acquisition or until the date of disposal, as appropriate. Adjustments have been made to the financial statements of subsidiaries to allow their accounting policies to be consistent with those used by the consolidated entities. During the preparation of the consolidated financial statements, the transaction, account balance, revenue and expense among entities have been eliminated completely. Subsidiaries' total comprehensive income is attributed to the owners of the Company and non-controlling interests, even if it results in losses for non-controlling interests.

Changes in the consolidated entities' ownership interests in subsidiaries that do not result in the Company's loss of control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the consolidated entities' interests and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. The price difference between the adjustment value of non-controlling interest and fair value of paid or collected consideration shall be stated into equity directly and also attributed to the owners of the Company.

Please refer to Note 12 and Table 3 for details of subsidiaries, percentage of ownership and business lines.

(4) Other significant accounting policies

In addition to the following notes, please also refer to the summarization of the significant accounting policies in the 2024 Annual Financial Report.

Income tax expense

The tax expenses include the sum of current and deferred income taxes. The interim income tax is evaluated based on the year; the tax rate applicable to the expected total annual earning is applied to calculate the interim pre-tax incomes.

5. Major sources of uncertainties to significant account judgments, estimates, and assumptions

The major sources of uncertainties to significant account judgments, estimates, and assumptions adopted herein are identical to those applied in the 2024 consolidated financial statements.

6. Cash and cash equivalents

	March 31, 2025	December 31, 2024	March 31, 2024
Cash on Hand	$ 372	$ 358	$ 401
Check and demand deposits	349,650	278,726	252,365
Cash equivalents (Investment due within three (3) months initially)			
Bank time deposits	1,159,634	1,008,979	941,000
Reverse repurchase agreements	33,205	70,000	-
	$ 1,542,861	$ 1,358,063	$ 1,193,766

7. Financial instruments carried at fair value through profit or loss

	March 31, 2025	December 31, 2024	March 31, 2024
Financial assets – current			
Mandatorily as at Fair Value Through Profit or Loss			
Non-derivative financial assets			
— TWSE (TPEx) Listed and Emerging Market Stocks	$ 53,775	$ 24,725	$ 38,437
— Foreign listed/over-the-counter stocks	15,003	14,372	76,141
— Fund beneficiary certificates	3,407	-	-
	$ 72,185	$ 39,097	$ 114,578

8. Financial assets carried at amortized cost

	March 31, 2025	December 31, 2024	March 31, 2024
Current			
Domestic investment			
Time deposits with an initial maturity of more than 3 months	$ 500,000	$ 221,963	$ 198,000
Demand deposits with restrictions on use	-	500,000	-
	$ 500,000	$ 721,963	$ 198,000
Non-current			
Domestic investment			
Time deposits with an initial maturity of more than 12 months	$ 54,040	$ 54,040	$ 4,040
Foreign investment			
Financial bonds	20,252	-	-
	$ 74,292	$ 54,040	$ 4,040

As of March 31, 2025, the effective interest rates of the above bonds ranged from 4.59% to 4.83%, and the bonds will mature in stages by February 1, 2029.

For details about the consolidated entities' time deposits pledged or provided as security, please refer to Note 25.

9. Notes receivable, accounts receivable and other receivables

	March 31, 2025	December 31, 2024	March 31, 2024
Notes receivable			
Total carrying amount carried at amortized cost	$ 2,152	$ 2,040	$ 2,898
Accounts receivable			
Total carrying amount carried at amortized cost	$ 209,833	$ 239,840	$ 178,072
Less: Allowance loss	-	-	-
	$ 209,833	$ 239,840	$ 178,072
Other accounts receivable	$ 9,810	$ 8,075	$ 7,494

(1) Notes and accounts receivable

The consolidated entities' average credit period for the sale of goods ranges from 30 days to 90 days. The accounts receivable are collected without interest. When determining the recoverability of accounts receivable, the consolidated entities shall consider any changes in the credit quality of the accounts receivable from the date of initial granting of the loan until the balance sheet date.

The consolidated entitles recognizes loss allowance for accounts receivable based on the lifetime expected credit loss, according to the streamlined approach under IFRS 9. The lifetime expected credit losses are calculated using the reserve matrix, by considering the customers' past default records and current financial position as well as the industrial economic situations, in addition to GDP forecast and industrial outlook. As the consolidated entities' credit loss history shows that there is no significant difference among the loss patterns of different customer bases, the reserve matrix doesn't further divide the customer bases, but only establishes the expected credit losses based on the number of days for which the accounts receivable becomes overdue.

The consolidated entities write off accounts receivable when there is information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery expectable by the consolidated entities. For accounts receivables that have been written off, the consolidated entities continue to engage in enforcement activity to attempt to recover the receivables due. Where recoveries are made, these are recognized in income.

The loss allowance for accounts receivable measured by the consolidated entities using the reserve matrix are as follows:

March 31, 2025

	Not overdue	Overdue 1–90 days	Overdue 91–180 days	Overdue 181–270 days	Overdue 271–360 days	Overdue more than 360 days	Total
Expected credit loss rate	0%	0%	0%	0%	0%	100%	
Total Carrying Amount	$ 167,197	$ 44,622	$ 163	$ 3	$ -	$ -	$ 211,985
Loss allowance (lifetime expected credit loss)	-	-	-	-	-	-	-
Amortized Cost	$ 167,197	$ 44,622	$ 163	$ 3	$ -	$ -	$ 211,985

December 31, 2024

	Not overdue	Overdue 1–90 days	Overdue 91–180 days	Overdue 181–270 days	Overdue 271–360 days	Overdue more than 360 days	Total
Expected credit loss rate	0%	0%	0%	0%	0%	100%	
Total Carrying Amount	$ 138,738	$ 103,139	$ 3	$ -	$ -	$ -	$ 241,880
Loss allowance (lifetime expected credit loss)	-	-	-	-	-	-	-
Amortized Cost	$ 138,738	$ 103,139	$ 3	$ -	$ -	$ -	$ 241,880

March 31, 2024

	Not overdue	Overdue 1–90 days	Overdue 91–180 days	Overdue 181–270 days	Overdue 271–360 days	Overdue more than 360 days	Total
Expected credit loss rate	0%	0%	0%	0%	0%	100%	
Total Carrying Amount	$ 128,647	$ 52,319	$ 4	$ -	$ -	$ -	$ 180,970
Loss allowance (lifetime expected credit loss)	-	-	-	-	-	-	-
Amortized Cost	$ 128,647	$ 52,319	$ 4	$ -	$ -	$ -	$ 180,970

The information about changes in loss allowance on the Company's accounts receivable is specified as follows:

	January 1 to March 31, 2025	January 1 to March 31, 2024
Balance – beginning and ending	$ -	$ -

(2) Other accounts receivable

When any objective evidence shows impairment on other receivables, the Company shall evaluate the amount of impairment individually. There should be no other receivables that were already past due but for which the consolidated entities have not yet recognized the loss allowance, on the balance sheet date.

10. Inventories

	March 31, 2025	December 31, 2024	March 31, 2024
Finished goods	$ 163,314	$ 175,171	$ 232,358
Work in process	339,482	291,193	444,872
Raw materials	178,313	204,412	160,908
	$ 681,109	$ 670,776	$ 838,138

On March 31, 2025 and December 31 and March 31, 2024, the allowance for inventory devaluation and loss amounted to NT$73,823 thousand, NT$73,510 thousand and NT$76,347 thousand.

Cost of sales:

	January 1 to March 31, 2025	January 1 to March 31, 2024
Cost of sold inventory	$ 164,683	$ 194,813
Loss (gain on recovery) on inventory devaluation and obsolescence	313	(5,087)
Unamortized manufacturing expense	1,067	3,679
Labor cost	542	12,028
	$ 166,605	$ 205,433

For the period from January 1 to March 31, 2024, the reversal of allowance for inventory valuation losses was mainly due to the recovery of the net realizable value of inventories.

11. Non-current assets held for sale

To adjust its overall operational strategy, reduce operating costs, and allocate resources effectively, the Company's Board of Directors resolved on May 3, 2024 to change its registration from Hsinchu Science Park to Southern Taiwan Science Park, and to dispose of the real estate building and its ancillary equipment located at No. 29, Kezhong Road, Zhunan Township, Miaoli County. The aforementioned real estate (with a book value of NT$136,501 thousand) was sold through public bidding. The transaction was completed on July 26, 2024, with a disposal price of NT$476,190 thousand (before tax). This transaction was approved by the review committee of the Hsinchu Science Park Bureau of the Ministry of Science and Technology on December 2, 2024, and the relevant assets have been reclassified as non-current assets held for sale. This transaction was completed on January 6, 2025, with the transfer of ownership, resulting in a recognized gain on disposal of NT$339,689 thousand.

As of December 31, 2024, advance payments received for the sale amounted to NT$500,000 (tax included). These funds were deposited into a dedicated trust account. Due to usage restrictions, they are recorded as financial assets at amortized cost – current.

(1) Non-current assets held for sale

	December 31, 2024
Property, plant and equipment	$ 136,501

(2) Liabilities directly related to non-current assets held for sale

	December 31, 2024
Advance receipts	$ 500,000

(3) No impairment loss has been incurred after re-measurement of the lower of the carrying amount of the non-current assets held for sale or the fair value thereof less cost of sale.

12. Subsidiary

The subsidiaries included in the consolidated financial statements

The entities in the consolidated financial statements are as follows:

			Percentage of ownership		
Name of investor	Name of subsidiary	Nature of business	March 31, 2025	December 31, 2024	March 31, 2024
The Company	SLC BioPharm Co., Ltd.	Biotechnology R&D and wholesale of western pharmaceuticals	100	100	100
The Company	Ruize Biotechnology Co., Ltd.	International Trade, Wholesale of Medical Devices and Retail Sale of Medical Apparatus	33.33	33.33	33.33
The Company	Pengrui Construction Co., Ltd.	Urban Renewal and Reconstruction, Investment Consulting	100	100	-
SLC BioPharm Co., Ltd.	Ruize Biotechnology Co., Ltd.	International Trade, Wholesale of Medical Devices and Retail Sale of Medical Apparatus	17.67	17.67	17.67

13. Investments Using the Equity Method

The consolidated entities' affiliates are listed as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Individual insignificant affiliate			
Huan Pin Construction Co., Ltd.	$ 147,176	$ 146,782	$ 146,466

	Percentage of ownership and voting rights		
Name	March 31, 2025	December 31, 2024	March 31, 2024
Huan Pin Construction Co., Ltd.	35%	35%	35%

For information about the business nature of said joint ventures, principal business place and country where the company is registered, please refer to the "Information on Names and Locations of Investees, etc." specified in table 3.

14. Property, plant and equipment

	March 31, 2025	December 31, 2024	March 31, 2024
House and building	$ 477,423	$ 481,884	$ 634,458
Machinery and equipment	87,443	96,786	125,726
Test equipment	1,428	1,626	2,647
Office equipment	392	530	361
Leasehold improvement	2,533	3,098	3,712
Other equipment	19,749	22,297	41,088
Uncompleted construction and equipment to be tested	153,146	121,836	21,370
	$ 742,114	$ 728,057	$ 829,362

Except the recognized depreciation expenses, no major additions to, disposal of or impairment on the consolidated entities' property, plant and equipment has taken place for the three-month periods ended March 31, 2025 and 2024. Depreciation expenses are provided on a straight-line basis over useful years shown as follows:

House and building	
Plant	21–51 years
Housing accessories	3–36 years
Machinery and equipment	2–20 years
Test equipment	5–9 years
Office equipment	3–7 years
Leasehold improvement	2–13 years
Other equipment	3–20 years

For the amounts of property, plant and equipment furnished to secure loans, please refer to Note 25.

15. Lease agreement

(1) Right-of-use assets

	March 31, 2025	December 31, 2024	March 31, 2024
Carrying Amount of Right-of-use Assets			
Land	$ 157,617	$ 158,653	$ 248,087
Buildings	6,754	4,873	9,595
Transport equipment	1,265	1,440	1,995
Other assets	1,749	1,874	4,498
	$ 167,385	$ 166,840	$ 264,175

	January 1 to March 31, 2025	January 1 to March 31, 2024
Addition to right-of-use assets.	$ 3,809	$ 12,789
Depreciation expenses of right-of-use assets		
Land	$ 1,036	$ 1,668
Buildings	1,928	1,886
Transport equipment	175	194
Other assets	125	250
	$ 3,264	$ 3,998

Except the recognized depreciation expenses, no major additions to, sublet of, or impairment on, the consolidated entities' right-of-use assets has taken place for the three-month periods ended March 31, 2025 and 2024.

(2) Lease liabilities

	March 31, 2025	December 31, 2024	March 31, 2024
The Carrying amount of the lease liability			
Current	$ 8,266	$ 8,201	$ 13,338
Non-current	$ 170,394	$ 169,584	$ 266,480

Discount rates of lease liabilities are as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Land	3.00%	3.00%	3.00%
Buildings	2.50-3.00%	2.75-3.00%	2.66~3.00%
Transport equipment	3.00-3.09%	3.00-3.09%	3.00-3.09%
Other equipment	3.09%	3.09%	3.09%

(3) Important lease activities and terms

The underlying assets of the consolidated entities' lease transactions include land, buildings, and company cars. Lease contracts usually have a term of 2 to 20 years. Lease contracts are negotiated individually and contain different terms and conditions. There are no restrictions in the contract, except that the assets under the lease shall not be used as collateral for loans. Upon termination of the lease period, the consolidated entities retain no preemptive right to purchase said lease.

For the objects specified in the variable lease payment terms of the consolidated entities' lease contract that are linked to the adjustment of the announced land price at the site of the consolidated entities' factory or the rental rate for lease of the state-owned land, the lease liabilities are reassessed because of the change in the lease payment resulting from the aforementioned rental adjustment in 2025 Q1 and 2024 Q1, and the right-of-use assets are adjusted based on the remeasurement to the amount of NT$0 thousand and NT$12,789 thousand, respectively.

(4) Other Leasing Information

	January 1 to March 31, 2025	January 1 to March 31, 2024
Expenses of Short-term Leases	$ 164	$ 138
Lease expense on low-value assets	$ 50	$ 44
Total cash (outflow) from lease	$ 4,480	$ 5,645

16. Other payables

	March 31, 2025	December 31, 2024	March 31, 2024
Salaries and bonuses payable	$ 31,602	$ 50,527	$ 33,077
Severance pay payable	-	-	16,015
Remuneration payable to employees and directors	38,265	20,635	5,757
Equipment payment payable	7,202	15,403	1,104
Others	40,846	36,840	54,354
	$ 117,915	$ 123,405	$ 110,307

Due to adjustments in the overall operational strategy, the Company transferred its registered location to the Southern Taiwan Science Park. For this relocation plan, a restructuring provision of NT$16,015 thousand was recognized as of March 31, 2024. Please refer to Note 19 (5) Employee Benefit Expenses. As of March 31, 2025, there is no remaining unpaid restructuring provision.

17. Equity

(1) Capital stock

Ordinary Shares

	March 31, 2025	December 31, 2024	March 31, 2024
Authorized number of shares (thousand shares)	350,000	350,000	350,000
Capital stock	$ 3,500,000	$ 3,500,000	$ 3,500,000
The number of issued and outstanding shares with paid-in capital (in thousand shares)	317,399	317,399	317,399
Issued capital stock	$ 3,173,991	$ 3,173,991	$ 3,173,991

The common stocks are issued with par value of NT$10 per share with one voting right and right to collect dividends for each.

(2) Capital surplus

	March 31, 2025	December 31, 2024	March 31, 2024
It can be applied for the make-up of losses, cash distribution, or capitalization (1)			
Issuance of shares at a premium	$ 108,661	$ 108,661	$ 108,661
Employee stock options transfer-in	19,207	19,207	19,092
Invalid convertible corporate bonds stock options	6,882	6,882	6,882
Not used for any purposes.			
Employee stock options	377	377	492
	$ 135,127	$ 135,127	$ 135,127

1. Such capital surplus can be used to make up for losses. When the Company suffers no losses, it can be applied for cash distribution or capitalization. However, it is limited to a certain percentage of the annual paid-in capital for the purpose of capitalization.

(3) Retained Earnings and Dividend Policy

According to the earnings distribution policy under the Company's Articles of Incorporation, if there is a surplus after account settlement of the fiscal year, the Company shall pay applicable taxes pursuant to laws and cover loss carried forward, followed by the allocation of 10% of the remainder as legal reserve. Subsequently, the Company shall contribute or reverse special reserve pursuant to laws. The balance, if any, plus the accumulated undistributed earnings in the past years, shall be distributed as dividends to shareholders per the motion for distribution of earnings proposed by the Board of Directors as resolved by a shareholders' meeting. According to the dividend policy, the Company shall set aside no less than 50% of the distributable earnings for the allocation of the shareholder bonus. However, the shareholder bonuses may not be distributed if the accumulated distributable earnings are less than 3% of the paid-in capital. The payment may be made in cash or shares, and the dividend in cash shall not be less than 5% of the total dividend. If the earnings referred to in the preceding paragraph are distributed in the form of cash dividends, the Board of Directors shall be authorized to make a resolution and report to the shareholders' meeting. Please refer to Note 19(6) "Remuneration to Employees and Directors" for the distribution of remuneration to employees and directors prescribed in the Company's Articles of Incorporation.

The Company shall set aside a legal reserve unless its total amount has reached the amount of the Company's total paid-in capital. The legal reserve may be used to offset a deficit. Where the Company doesn't operate at a loss, the part of the legal reserve in excess of 25% of the paid-in capital could be applied for capitalization and may be allocated in cash as well.

The Company's 2024 and 2023 earnings appropriation plans are stated as follows:

	2024	2023
Legal reserve	$ 18,238	$ 3,003
Cash dividend	$ 126,960	$ 27,027
Cash dividend per share (NT$)	$ 0.4000	$ 0.0851

Said cash dividends were resolved to be distributed by the Board of Directors meeting on May 2, 2025, and May 3, 2024, respectively. The other earnings appropriation plan for 2024 was also resolved by the annual general meeting on June 13, 2025. The remaining items of the 2023 earnings distribution were approved by resolution at the annual general meeting held on June 14, 2024.

18. Operating Revenue

Product and service type	January 1 to March 31, 2025	January 1 to March 31, 2024
Revenue from customer contracts		
Revenue from the sale of products	$ 263,240	$ 243,548
Labor service revenue	621	15,644
	$ 263,861	$ 259,192

(1) Remark on customer contracts

1. The revenue from R&D services and process design of the consolidated entities is generated from the development of new drugs and process designs as described below:

   (1) The consolidated entities entered into a process design agreement with Customer Z in November 2018 to provide process design services for the setup of oral tablet production lines for the new drug SLC-029.

   The income from the process design was mainly based on the transaction price allocated to the contractual obligations and recognized according to the progress of these obligations. The completion percentage of the services was determined based on the proportion of the actually disbursed cost in the estimated total cost. Process validation and batch production will be conducted after the setup of the production lines for batch manufacturing before mass production of the new drug. The consolidated entities will recognize a service income based on the progress.

(2) The consolidated entities entered into the technology transfer and batch production contracts with Customer X in June 2022. Under the contracts, the consolidated entities allocated the transaction price primarily based on the contract performance obligations at the stages including technology transfer, batch production and product test, and recognized the revenue when the contract performance obligation was satisfied.

(3) The consolidated entities entered into the process design contracts with Customer Y in July 2023. Under the contracts, the consolidated entities allocated the transaction price primarily based on the contract performance obligations at the stages, including the process development, development of analysis method and experimental sample stability research and recognized the revenue when the contract performance obligation was satisfied.

2. The fee-splitting under drug license and authorized sale is as follows:

The consolidated entities authorize a leading international pharmaceutical company as the sole agent to sell the ertapenem injection medicine for which the consolidated entities have acquired the drug license in the USA. In addition to receiving a fixed upfront payment based on the progress according to the agreement, the consolidated entities and the pharmaceutical company are subject to a fee splitting and profit sharing mechanism according to the agreement, and the consolidated entities recognize an agreed percentage of the net profit defined in the agreement in revenue in consideration of the sales status of the pharmaceutical company.

(2) Contract Balance

	March 31, 2025	December 31, 2024	March 31, 2024
Accounts receivable (Note 9)	$ 209,833	$ 239,840	$ 178,072
Contract liabilities – current	$ 3,071	$ 13,947	$ 6,055

(3) Breakdown of revenue from customer contracts

January 1 to March 31, 2025

	Antibiotics	Others	Total
Customer contract income recognized at a certain time point	$ 248,778	$ 15,083	$ 263,861
Income recognized individually along the timeline	-	-	-
	$ 248,778	$ 15,083	$ 263,861

January 1 to March 31, 2024

	Antibiotics	Others	Total
Customer contract income recognized at a certain time point	$ 226,927	$ 24,025	$ 250,952
Income recognized individually along the timeline	-	8,240	8,240
	$ 226,927	$ 32,265	$ 259,192

19. Items of net income before tax

(1) Interest revenue

	January 1 to March 31, 2025	January 1 to March 31, 2024
Bank deposits	$ 10,297	$ 8,833
Financial assets carried at amortized cost	3,686	870
Others	156	191
	$ 14,139	$ 9,894

(2) Other gains and losses

	January 1 to March 31, 2025	January 1 to March 31, 2024
Loss on disposal of property, plant, and equipment	($ 188)	$ -
Gain on disposal of non-current assets held for sale (Note 11)	339,689	-
Gain (loss) from financial assets at fair value through profit or loss	(5,394)	28,999

(Continued on the next page)

(Brought forward)

	January 1 to March 31, 2025	January 1 to March 31, 2024
Net gain on foreign exchange	$ 13,967	$ 34,660
Others	(5,216)	(41)
	$ 342,858	$ 63,618

(3) Financial cost

	January 1 to March 31, 2025	January 1 to March 31, 2024
Interest on Lease Liabilities	$ 1,332	$ 2,116

(4) Depreciation and impairment expenses

	January 1 to March 31, 2025	January 1 to March 31, 2024
Property and equipment	$ 20,833	$ 32,937
Right-of-use assets	3,264	3,998
Intangible assets	472	627
	$ 24,569	$ 37,562
Summarization of depreciation expenses by function		
Operating costs	$ 19,494	$ 28,463
Operating expenses	4,603	8,472
	$ 24,097	$ 36,935
Summarization of amortization expenses by function		
Operating costs	$ 420	$ 558
Operating expenses	52	69
	$ 472	$ 627

(5) Employee benefit expense

	January 1 to March 31, 2025	January 1 to March 31, 2024
Short-term employee benefits		
Payroll expense	$ 74,330	$ 68,181
Labor and health insurance expense	6,270	6,271
Post-employment Benefits	2,584	3,031

(Continued on the next page)

(Brought forward)

	January 1 to March 31, 2025	January 1 to March 31, 2024
Other employee benefits	$ 3,884	$ 4,982
Resignation benefits	-	16,015
Total employee benefit expense	$ 87,068	$ 98,480
Summarization by function		
Operating costs	$ 44,379	$ 64,417
Operating expenses	42,689	34,063
	$ 87,068	$ 98,480

(6) Remuneration to employees and directors

According to the Articles of Incorporation, if there is profit for the year, the Company shall set aside no less than 3% thereof as remuneration to employees and no more than 3% as remuneration to directors. However, the profit must first be used to cover the Company's cumulative loss, if any. Pursuant to the August 2024 amendment to the Securities and Exchange Act, the Company plans to seek shareholder approval at the 2025 Annual General Meeting to amend its Articles of Incorporation to specify that 20% of the employee remuneration allocated for the year shall be distributed to non-executive employees. The estimated remuneration to employees (including non-executive employees) and directors for the three-month periods ended March 31, 2025 and 2024 is stated as follows:

Estimated ratio

	January 1 to March 31, 2025	January 1 to March 31, 2024
Remuneration to Employees	3.02%	3.3%
Remuneration to Directors	1.50%	2.2%

Amount

	January 1 to March 31, 2025	January 1 to March 31, 2024
Remuneration to Employees	$ 12,200	$ 2,482
Remuneration to Directors	$ 6,065	$ 1,655

Changes in the amount after the publication date of the annual consolidated financial report will be treated as changes in accounting estimates and adjusted in the following year.

The 2024 and 2023 remunerations to employees and directors were resolved as follows by the Board of Directors on March 6, 2025 and March 8, 2024:

Amount

	2024	2023
Remuneration to Employees	$ 14,000	$ 1,000
Remuneration to Directors	$ 3,000	$ 620

On March 6, 2025, the Company's Board of Directors resolved on the distribution of director remuneration. As a result, the actual amount distributed differed from the amount recognized in the annual consolidated financial statements, and the difference has been adjusted in the 2025 profit or loss.

	2024 Remuneration to Directors
Amount resolved for distribution by the Board	$ 3,000
Amount recognized in the annual financial statements	$ 6,000

Please visit the Market Observation Post System (MOPS) for information on employee remuneration and directors' remuneration approved by the Board of Directors.

20. Income tax

(1) Main elements of total income tax expenses recognized in profit or loss

	January 1 to March 31, 2025	January 1 to March 31, 2024
Current income tax		
Those generated in the current period	$ -	$ -
Deferred income tax		
Those generated in the current period	-	-
Total Income Tax Expense Recognized in Profit or Loss	$ -	$ -

(2) The status of income tax returns filed by the parent company and subsidiaries, as assessed by the tax authorities, is as follows:

	Approved fiscal year
Parent company	2021
SLC BioPharm Co., Ltd.	2023
Ruize Biotechnology Co., Ltd.	2023

21. Earnings Per Share

Unit: NTD per share

	January 1 to March 31, 2025	January 1 to March 31, 2024
Basic EPS	$ 1.22	$ 0.22
Diluted EPS	$ 1.21	$ 0.22

The net income and weighted average number of common stocks used to calculate earnings per share are enumerated below:

Current net profit

	January 1 to March 31, 2025	January 1 to March 31, 2024
Net income used to calculate basic and diluted earnings per share	$ 386,076	$ 71,073

Number of shares

Unit: thousand shares

	January 1 to March 31, 2025	January 1 to March 31, 2024
Weighted average number of common stocks is used to calculate basic earnings per share	317,399	317,399
Effect of dilutive potential common stocks:		
Employee stock options	11	1
Remuneration to Employees	1,140	163
Weighted average number of common stocks is used to calculate diluted earnings per share	318,550	317,563

If the consolidated entities offer to settle the remuneration to employees in cash or shares, when calculating diluted earnings per share, the consolidated entities need to assume that the entire amount of the remuneration to employees will be settled in shares, and the resulting potential shares shall be included in the weighted average number of common stocks used in the computation of diluted earnings per share, as the effect is dilutive. Such a dilutive effect on the potential shares should be included in the computation of diluted earnings per share until the number of shares to be distributed to employees is resolved in the next year.

22. Share-based payment agreement

The consolidated entities didn't issue additional employee stock options for the three-month periods ended March 31, 2025 and 2024. The information about the outstanding employee stock options is specified as follows:

Employee stock options	January 1 to March 31, 2025 Unit (thousand)	January 1 to March 31, 2025 Weighted average exercise price (NT$)	January 1 to March 31, 2024 Unit (thousand)	January 1 to March 31, 2024 Weighted average exercise price (NT$)
Outstanding shares, beginning	116	$ 16.50	670	$ 22.93
Forfeited in this period	-	-	(519)	24.80
Outstanding shares, ending	116	16.50	151	16.50
Exercisable shares, ending	116	16.50	151	16.50

The remuneration costs recognized by the consolidated entities were both NT$0 thousand for the three-month periods ended March 31, 2025 and 2024.

23. Financial instruments

(1) Fair value information – Financial instruments not carried at fair value

March 31, 2025

	Carrying Amount	Fair value Level 1	Fair value Level 2	Fair value Level 3	Fair value Total
Financial assets					
Financial assets carried at amortized cost					
— Foreign financial bonds	$ 20,252	$ -	$ 20,149	$ -	$ 20,149

(2) Fair value information – Financial instruments at fair value on a recurring basis

Fair Value Hierarchy

March 31, 2025

	Level 1	Level 2	Level 3	Total
Financial assets carried at fair value through profit or loss				
TWSE (TPEx) Listed Stocks	$ 53,775	$ -	$ -	$ 53,775
Foreign listed/over-the-counter stocks	15,003	-	-	15,003
Fund beneficiary certificates	3,407	-	-	3,407
	$ 72,185	$ -	$ -	$ 72,185

December 31, 2024

	Level 1	Level 2	Level 3	Total
Financial assets carried at fair value through profit or loss				
TWSE (TPEx) Listed Stocks	$ 24,725	$ -	$ -	$ 24,725
Foreign listed/over-the-counter stocks	14,372	-	-	14,372
	$ 39,097	$ -	$ -	$ 39,097

March 31, 2024

	Level 1	Level 2	Level 3	Total
Financial assets carried at fair value through profit or loss				
Domestic emerging stocks	$ 38,437	$ -	$ -	$ 38,437
Foreign listed/over-the-counter stocks	76,141	-	-	76,141
	$ 114,578	$ -	$ -	$ 114,578

There was no transfer of fair value measurement between Level 1 and Level 2 for the three-month periods ended March 31, 2025 and 2024.

(3) Type of financial instruments

	March 31, 2025	December 31, 2024	March 31, 2024
Financial assets			
Measured at fair value through profit or loss	$ 72,185	$ 39,097	$ 114,578
Financial assets carried at amortized cost (Note 1)	2,343,451	2,388,426	1,588,748
Financial liabilities			
Financial liabilities carried at amortized cost (Note 2)	158,271	165,644	167,235

Note 1: The balances include the financial assets carried at amortized cost, such as cash and cash equivalents, financial assets carried at amortized cost, net notes receivable, net accounts receivable, other receivables and refundable deposits (stated as other non-current assets).

Note 2: The balance includes accounts payable and other payables measured at amortized cost as financial liabilities.

(4) Financial Risk Management Objectives and Policies

The Group’s main financial instruments include investments in equity instruments, accounts receivable, accounts payable, and lease liabilities. The routine operation of the consolidated entities is affected by many financial risks, including market risk (including the foreign exchange rate risk, interest rate risk and price risk), credit risk and liquidity risk. The overall risk management policy of the consolidated entities emphasizes unpredictable events on the financial market. We are dedicated to reducing the potential effect on the financial status and performance of the consolidated entities.

The financial department is responsible for carrying out the risk management tasks of the consolidated entities pursuant to the policies approved by the Board of Directors. The financial department works closely with the operating unit of the consolidated entities to identify, assess and avoid financial risk.

1. Market risk

   The consolidated entities' operating activities expose them primarily to the financial risks of changes in foreign currency exchange rates (please refer to the following subparagraph (1)) and interest rates (please refer to the following subparagraph (2)).

   (1) Foreign exchange rate risk

   The consolidated entities engaged in foreign currency-denominated sales and purchases and, therefore, exposed themselves to the risk of foreign exchange rate changes.

   For the carrying amount of the consolidated entities' non-functional currency-denominated monetary assets and liabilities (including the non-functional currency-denominated monetary items already written off in the consolidated financial statements) on the balance sheet date, please see Note 28.

   Sensitivity analysis

   The consolidated entities are primarily exposed to the fluctuation in foreign exchange rate in USD. For the significant assets and liabilities generated from the foreign currency-denominated transactions, the foreign currency-denominated assets and liabilities may offset against each other based on the income generated from the changes in the foreign exchange rate in the market. Notwithstanding, as the consolidated entities' foreign currency-denominated assets are more than the foreign currency-denominated liabilities, the consolidated entities have to bear the foreign exchange rate risk.

   The sensitivity analysis on the consolidated entities aims at the foreign currency-denominated monetary items on the balance sheet date, and their translation at the end of the year is adjusted by changes in exchange rates of 1%. When USD against NTD appreciates by 1%, the profit before tax for the three-month periods ended March 31, 2025 and 2024 will increase by $11,319 thousand and $8,452 thousand, respectively.

(2) Other Price Risk

The equity securities market risk includes the risk arising from changes in the equity securities market price, namely the general market risk arising from changes in the overall market price. When the equity price declines by 1%, the consolidated entities' income before tax will decrease by $722 thousand and $1,146 thousand, respectively, due to the changes in the financial assets carried at fair value through profit or loss for the three-month periods ended on March 31, 2025 and 2024.

2. Credit risk

Credit risk refers to the risk that a trading counterpart will default on its contractual obligations and thereby result in the risk of financial loss to the consolidated entities. Until the balance sheet date, the consolidated entities' maximum exposure to credit risk (irrespective of collaterals or other credit enhancement instruments, and irrevocable), which would cause a financial loss to the consolidated entities due to a trading counterpart's failure to discharge contractual obligation and the consolidated entities' provision of financial guarantee, would have primarily been caused by the carrying amount of the financial assets recognized in the consolidated balance sheets.

According to the documented internal credit policy, the consolidated entities must carry out the customer management and credit risk analysis for each new customer before establishing payment terms and delivery conditions with the new customer. Internal risk control is performed in consideration of the financial status of the customer, previous experience and other factors to assess the credit quality of the customer. The credit facilities with respect to individual risks are determined by the Board of Directors pursuant to internal or external rating. Use of the credit facilities is monitored on a regular basis.

3. Liquidity risk

The cash flow forecast is implemented by the management of the consolidated entities and summarized by the financial department. The financial department monitors the forecast of the consolidated entities' liquidity demands to ensure sufficient funds for the business operation. The financial department also maintains adequate unused loan commitment limits at all times to ensure the consolidated entities will not act in violation of related loan limits or terms. The forecast is subject to consideration of the consolidated entities' financing plan, compliance with liability clauses, and conformity to the financial ratio in the internal balance sheet.

(1) Statement of liquidity and interest risk rate of non-derivative financial liabilities

The analysis on the remaining contractual maturity for the non-derivative financial liabilities is prepared based on the undiscounted cash flows of financial liabilities from the earliest date on which the consolidated entities (including the principal and estimated interest) can be required to pay. The analysis on the maturity dates for the consolidated entities' non-derivative financial liabilities is prepared based on the agreed repayment dates.

March 31, 2025

	Less than 3 months	3 months–1 year	1–5 years	Over 5 years
Non-derivative financial liabilities				
Accounts payable	$ 36,386	$ 3,970	$ -	$ -
Other payables	63,538	54,377	-	-
Lease liabilities	4,356	9,115	34,074	246,505
	$ 104,280	$ 67,462	$ 34,074	$ 246,505

December 31, 2024

	Less than 3 months	3 months–1 year	1–5 years	Over 5 years
Non-derivative financial liabilities				
Accounts payable	$ 38,355	$ 3,884	$ -	$ -
Other payables	97,402	26,003	-	-
Lease liabilities	4,095	9,300	32,660	248,364
	$ 139,852	$ 39,187	$ 32,660	$ 248,364

March 31, 2024

	Less than 3 months	3 months–1 year	1–5 years	Over 5 years
Non-derivative financial liabilities				
Accounts payable	$ 54,419	$ 2,509	$ -	$ -
Other payables	107,903	2,404	-	-
Lease liabilities	5,463	16,087	54,683	379,648
	$ 167,785	$ 21,000	$ 54,683	$ 379,648

(2) Facility

	March 31, 2025	December 31, 2024	March 31, 2024
Bank facility			
— Amount already disbursed	$ -	$ -	$ -
— Amount not yet disbursed	700,000	600,000	730,000
	$ 700,000	$ 600,000	$ 730,000

24. Transactions with related parties

The transactions, account balances, income and expenses between the Company and its subsidiaries (the Company's related parties) have been eliminated on consolidation and, therefore, are not disclosed in the Note.

Remuneration to key management

	January 1 to March 31, 2025	January 1 to March 31, 2024
Short-term employee benefits	$ 17,727	$ 8,657

Total salary and compensation to directors and other key management are decided by the Remuneration Committee based on personal performance and market trend.

25. Pledged and mortgaged assets

The following assets of the consolidated entities are provided as collateral for bank guarantees, bank facility and right-of-use assets:

	March 31, 2025	December 31, 2024	March 31, 2024
Time deposits (stated as financial assets measured at amortized cost – non-current)	$ 4,040	$ 4,040	$ 4,040
Property, plant and equipment	464,865	468,827	606,175
Refundable deposits (stated as other non-current assets)	4,502	4,405	4,478
	$ 473,407	$ 477,272	$ 614,693

26. Significant contingent liabilities and unrecognized contractual commitments

The consolidated entities' significant commitments on the balance sheet date, in addition to those already specified in other notes, are specified as follows:

(1) As of March 31, 2025, December 31, 2024, and March 31, 2024, the consolidated entities' letters of credit issued but not used amounted to US$0 thousand, US$0 thousand and US$74 thousand, respectively.

(2) The contractual commitments which the consolidated entities have not yet recognized are specified as follows:

	March 31, 2025	December 31, 2024	March 31, 2024
Purchase of property, plant and equipment	$ 84,431	$ 91,235	$ 68,179

27. Significant post-period items

On April 9, 2025, the Board of Directors resolved to repurchase 8,000 thousand shares of treasury stock between April 10 and June 9, 2025. The purpose of the repurchase is to maintain the Company's credibility and protect shareholder interests. The maximum total amount allocated for the repurchase is NT$325,143 thousand, with the repurchase price range set between NT$13 and NT$22 per share. If the share price falls below the lower limit of the range, the Company will continue to repurchase shares. The planned repurchase represents 2.52% of the Company's total issued shares. As of May 2, 2025, the Company had repurchased 2,408 thousand shares for a total amount of NT$43,247 thousand.

28. Information on the foreign currency assets and liabilities with significant impact

The following information is summarized according to the foreign currencies other than the functional currency of each of the consolidated entities. The foreign exchange rates disclosed are used to translate the foreign currency into the functional currency. Foreign currency assets and liabilities with significant impact are as follows:

March 31, 2025

	Foreign Currency	Foreign exchange rate	Carrying Amount
Foreign currency assets			
Monetary items			
USD	$ 34,319	33.205 (USD:NTD)	$ 1,139,574
Non-monetary items			
USD	452	33.205 (USD:NTD)	$ 15,003
Foreign currency liabilities			
Monetary items			
USD	231	33.205 (USD:NTD)	$ 7,680
Non-monetary items			
USD	89	33.205 (USD:NTD)	$ 2,864

December 31, 2024

	Foreign Currency	Foreign exchange rate	Carrying Amount
Foreign currency assets			
Monetary items			
USD	$ 32,903	32.785 (USD:NTD)	$ 1,078,734
Non-monetary items			
Financial assets carried at fair value through profit or loss			
USD	438	32.785 (USD:NTD)	$ 14,372
Foreign currency liabilities			
Monetary items			
USD	524	32.785 (USD:NTD)	$ 17,186
Non-monetary items			
USD	426	32.785 (USD:NTD)	$ 13,742

March 31, 2024

	Foreign Currency	Foreign exchange rate	Carrying Amount
Foreign currency assets			
Monetary items			
USD	$ 27,558	32.00 (USD:NTD)	$ 881,866
Non-monetary items			
Financial assets carried at fair value through profit or loss			
USD	2,379	32.00 (USD:NTD)	$ 76,141
Foreign currency liabilities			
Monetary items			
USD	1,144	32.00 (USD:NTD)	$ 36,620
Non-monetary items			
USD	196	32.00 (USD:NTD)	$ 6,055

(Unrealized) exchange gains or losses on foreign currency assets and liabilities with significant impact are specified as follows:

Functional currencies of entities holding foreign currencies	January 1 to March 31, 2025		January 1 to March 31, 2024	
	Foreign exchange rate	Net exchange (losses) gains	Foreign exchange rate	Net exchange (losses) gains
USD	33.205 (USD:NTD)	$ 1,711	32.00 (USD:NTD)	$ 957

29. Disclosure of notes

(1) Information on material transactions and (2) investees:

1. Loans to others: None.
2. Endorsements/guarantees for others: None.
3. Significant marketable securities held – ending (excluding those controlled by invested subsidiaries, associates and joint ventures): Table 1.
4. Purchases or sales of goods from and to related parties reaching NT$100 million or more than 20% of paid-in capital: None.
5. Accounts receivable from related parties reaching NT$100 million or more than 20% of the paid-in capital: None.
6. Business Relations and Significant Transactions Between Parent Company and Subsidiaries and Among Subsidiaries and Amounts: Table 2.

7. Information on investees: Table 3.

(3) Information on investment in China

1. Investees' name, business operations, paid-in capital, investment method, capital inward or outward, shareholding ratio, current gains or losses, and recognized investment gains or losses, investment year end carrying amount, investment gain or loss inward, and investment limits in mainland China: None.
2. Any of the following significant transactions with investees in mainland China, either directly or indirectly through a third party, and their prices, payment terms, and unrealized gains or losses:
   (1) Purchase amount and percentage and the related payables ending balance and percentage: None.
   (2) Sale amount and percentage and the related receivables ending balance and percentage: None.
   (3) The amount of property transactions and the amount of the resultant gains or losses: None.
   (4) The balance of negotiable instrument endorsements or guarantees or pledges of collateral at the end of the year and the purposes: None.
   (5) The highest balance, end of period balance, interest rate range, and total current interest with respect to financing of funds: None.
   (6) Other transactions that have a material effect on the profit or loss for the period or on the financial position, such as the provision or acceptance of services: None.

30. <u>Segment information</u>

The consolidated entities only need to disclose the business unit information about the medicine products department. The medicine products department is primarily engaged in medicine research, development, design, manufacturing and sales. The consolidated entities consist of only one single business unit and, therefore, have no segment information to be reported.

Savior Lifetec Corporation and its Subsidiaries

Significant marketable securities held at the end of the period

March 31, 2025

Table 1

Unit: Amounts in Thousand New Taiwan Dollars, Unless Otherwise Specified

Holding company	Type and name	Relationship with the issuer of securities	Account title	End of period				Remarks
				Number of shares/units	Carrying Amount	Shareholding percentage	Fair value	
Savior Lifetec Corporation	Bonds							
	MS 5.123 02/01/29 Corp	—	Financial assets measured at amortized cost – non-current	300	$ 10,142	-	$ 10,110	Note 1
	MS F 04/13/28 Corp	—	Financial assets measured at amortized cost – non-current	300	10,110	-	10,039	Note 1
	Stock							
	Sana Biotechnology, Inc.	—	Financial assets carried at fair value through profit or loss – current	268,940	15,003	0.120%	15,003	Note 2
	Taiwan Semiconductor Manufacturing Co., Ltd.	—	Financial assets carried at fair value through profit or loss – current	24,000	21,840	-	21,840	Note 2
	AblePrint Technology Co., Ltd.	—	Financial assets carried at fair value through profit or loss – current	13,000	14,755	-	14,755	Note 2
	Material - KY	—	Financial assets carried at fair value through profit or loss – current	20,000	17,180	-	17,180	Note 2

Note 1: For items that are not measured at fair value, the book value is the amortized cost (less loss allowance).

Note 2: The fair value was calculated based on the closing price on March 31, 2025.

Note 3: For information about investments in subsidiaries, please refer to Table 3.

Note 4: This table is prepared by the Company based on the materiality principle to disclose marketable securities that are required to be listed.

Savior Lifetec Corporation and its Subsidiaries

Business Relations and Significant Transactions Between Parent Company and Subsidiaries and Among Subsidiaries and Amounts

Three-Month Period Ended March 31, 2025

Table 2

Unit: NT$ thousand

No. (Note 1)	Name of Trader	Counterparty	Relationship with the transaction party (Note 2)	Transaction			
				Subject	Amount	Transaction Terms	As a Percentage of Total Consolidated Revenue or Total Assets
0	The Company	Ruize Biotechnology Co., Ltd.	1	Sales revenue	$ 5,825	Subject to the price agreed by both parties	2%
		Ruize Biotechnology Co., Ltd.	1	Accounts receivable - related parties	6,116	Subject to the price agreed by both parties	-

Note 1: The information on business transactions between the parent and subsidiaries shall be indicated in the number column. The number shall be filled in as follows:

(1) The parent company is coded “0”.

(2) The subsidiaries are coded sequentially beginning from “1” by each individual company.

Note 2: There are three types of relationships with transaction parties, just enter the code (if it is the same transaction between parent and subsidiary or between subsidiaries, there is no need for repeated disclosure. For example, if the parent company has disclosed a transaction between it and a subsidiary, the subsidiary does not need to disclose the transaction again; if a subsidiary has disclosed a transaction between it and another subsidiary, the latter does not need to disclose the transaction again):

(1) Parent to subsidiary.

(2) Subsidiary to parent.

(3) Between subsidiaries.

Note 3: The transaction amount as a percentage of the total consolidated revenue or total assets shall be calculated as the ratio of the ending balance to the total consolidated assets if it is an asset or liability item, or as the ratio of the interim cumulative amount to the total consolidated revenue if it is a profit or loss item.

Note 4: The Company may decide whether to list important transactions in this table based on the principle of materiality.

Note 5: Only transactions amounting to more than NT$1 million are disclosed, and no corresponding transactions with related parties are disclosed separately.

Note 6: It has been written off in whole at the time of preparation of the consolidated financial statements.

Savior Lifetec Corporation and Its Subsidiaries

Information on Names and Locations of Investees, etc.

Three-Month Period Ended March 31, 2025

Table 3

Unit: NT$ thousand

Name of investor	Name of Investee	Location	Main Business Activities	Initial Investment Amount		Held at End of Period			Investment Income or Loss on Investees	Investment Income or Loss Recognized for this Period	Remarks
				End of Current Period	End of Last Year	Number of shares (thousand shares)	Percentage (%)	Carrying Amount			
The Company	SLC BioPharm Co., Ltd.	Taipei City	Biotechnology R&D and wholesale of western pharmaceuticals	$ 110,000	$ 110,000	11,000	100	$ 41,635	($ 2,011)	($ 2,007)	Notes 1 and 2
The Company	Ruize Biotechnology Co., Ltd.	Taichung City	International Trade, Wholesale of Medical Devices and Retail Sale of Medical Apparatus	10,000	10,000	1,000	33.33	5,190	(1,934)	(645)	Notes 1 and 2
The Company	Pengrui Construction Co., Ltd.	Taipei City	Urban Renewal and Reconstruction, Investment Consulting	241,000	241,000	24,100	100	242,340	635	635	Notes 1 and 2
SLC BioPharm Co., Ltd.	Ruize Biotechnology Co., Ltd.	Taichung City	International Trade, Wholesale of Medical Devices and Retail Sale of Medical Apparatus	5,300	5,300	530	17.67	2,538	(1,934)	(342)	Notes 1 and 2
Pengrui Construction Co., Ltd.	Huan Pin Construction Co., Ltd.	Taipei City	Residential and building development, leasing and sales business, and urban renewal and reconstruction business	147,000	147,000	14,700	35	147,176	1,125	394	Notes 1 and 3

Note 1: Calculated based on the investee's financial statements for the same period audited by CPAs.

Note 2: It has been written off in whole at the time of preparation of the consolidated financial statements.

Note 3: Refers to investees accounted for using the equity method by the Company.